Nanomedicine beyond tumor passive targeting: what next?

João Paulo Figueiró Longo; Luís Alexandre Muehlmann

doi:10.2217/nnm-2020-0208

Nanomedicine beyond tumor passive targeting: what next?

Nanomedicine (Lond). 2020 Aug;15(19):1819-1822. doi: 10.2217/nnm-2020-0208. Epub 2020 Jul 17.

Authors

João Paulo Figueiró Longo¹, Luís Alexandre Muehlmann²

Affiliations

¹ Institute of Biological Sciences, University of Brasília, Brasília - DF 70910-900, Brazil.
² Faculty of Ceilândia, University of Brasília, Brasília - DF 72220-900, Brazil.

PMID: 32677536
DOI: 10.2217/nnm-2020-0208

No abstract available

Keywords: chemotherapy; clinical translation; clinical trials; healthcare; lipid nanoparticles; liposome; nanomedicine; perspectives; pharmacokinetics; preclinical studies.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Nanomedicine
Nanoparticles*
Neoplasms* / drug therapy